Radiopharm Theranostics Limited
- Open
- 2.29
- Day high
- 2.37
- Day low
- 2.19
- Prev close
- 2.41
- Volume
- 49K
- Mkt cap
- $33M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.9
- P/S
- 17.0
- Yield
- —
- Per share
- —
Radiopharm Theranostics Limited (RADX) is a Healthcare company listed on NASDAQ. The stock is down 59% over the past year. Drillr has 1 published research article covering RADX.
Radiopharm Theranostics Limited (RADX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RADX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 28, 2026 | $-1.67 | $-1.67 | +0.0% | $845235 | +0.0% |
Radiopharm Theranostics Limited company profile
Overview
Radiopharm Theranostics Limited (ASX:RAD) is a clinical-stage biotechnology company founded in 2021 and based in Carlton, Australia. The company recently went public in December 2024, representing one of the newest entrants in the radiopharmaceutical space. Radiopharm focuses on developing next-generation radiopharmaceutical products that combine diagnostic imaging with targeted therapeutic applications, addressing areas of high unmet medical need in oncology.
Business
Radiopharm Theranostics operates in the specialized field of radiopharmaceuticals, which represents the intersection of nuclear medicine, oncology, and precision medicine. Radiopharmaceuticals are radioactive compounds that can be used both to diagnose and treat cancer by targeting specific molecular markers on tumor cells. The company's approach centers on theranostics - a portmanteau of "therapy" and "diagnostics" - which allows the same targeting mechanism to be used for both imaging tumors and delivering targeted radiation therapy. This dual-purpose approach enables physicians to first identify patients who are likely to respond to treatment through diagnostic imaging, then deliver personalized radiation therapy directly to cancer cells while minimizing damage to healthy tissue. Radiopharm's pipeline includes several key programs targeting different cancer types. RAD 204 targets PD-L1 (programmed death-ligand 1) for non-small cell lung cancer treatment. RAD 202 focuses on HER2 (human epidermal growth factor receptor 2) for breast cancer and other solid tumors. The company is also developing RAD 301, a diagnostic agent targeting avß6 integrin in pancreatic cancer patients, along with RAD 302 as its therapeutic counterpart. Additional programs include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumor types. The radiopharmaceutical industry has gained significant momentum in recent years, driven by advances in targeted alpha therapy and the success of companies like Novartis with Lutathera and Pluvicto. This field represents a paradigm shift from traditional chemotherapy's broad cytotoxic approach to precision medicine that can selectively target cancer cells based on their molecular characteristics.
Revenue model
Radiopharm operates under a typical biotech business model focused on drug development and eventual commercialization through multiple pathways. The company currently generates minimal revenue, with approximately $200,000 in annual revenue likely from research grants or collaboration activities, while investing heavily in research and development. The company's primary revenue strategy will likely involve licensing partnerships with larger pharmaceutical companies, as evidenced by its strategic agreement with Lantheus Holdings, a established player in the nuclear medicine space. Such partnerships typically involve upfront payments, milestone payments during clinical development, and royalties on eventual sales. Additionally, the company may pursue direct commercialization in certain markets, particularly for diagnostic applications which often have lower regulatory barriers than therapeutics. The radiopharmaceutical market presents unique manufacturing and distribution challenges that could significantly impact margins. Radioactive compounds have short half-lives, requiring specialized production facilities and rapid distribution networks. This creates both barriers to entry and potential margin pressures. However, the specialized nature of radiopharmaceuticals also commands premium pricing, with successful products often generating substantial margins. Key factors that could positively impact margins include successful clinical trials leading to regulatory approval, strategic partnerships with established nuclear medicine companies, and the development of longer-lasting isotopes that reduce manufacturing and distribution complexity. Negative margin factors include the high cost of specialized manufacturing facilities, regulatory delays that extend development timelines, competition from larger pharmaceutical companies with established nuclear medicine capabilities, and the technical complexity of handling radioactive materials which requires specialized expertise and infrastructure.
Competitive moat
Radiopharm's competitive position is characteristic of early-stage biotech companies - potentially strong if successful, but currently unproven. The company's primary potential moat lies in its intellectual property portfolio around specific targeting mechanisms and radiopharmaceutical formulations. The radiopharmaceutical field requires specialized expertise in nuclear chemistry, regulatory pathways, and manufacturing processes that create natural barriers to entry. However, the company faces significant competitive threats from well-established players. Large pharmaceutical companies like Novartis, which has already commercialized multiple radiopharmaceuticals, possess substantial advantages in manufacturing capabilities, regulatory expertise, and distribution networks. The specialized infrastructure required for radiopharmaceutical production - including cyclotrons, hot cells, and qualified personnel - represents both a barrier to new entrants and a potential weakness for small companies lacking these resources. Radiopharm's partnership with Lantheus provides some strategic protection by leveraging an established player's infrastructure and expertise. However, this relationship also creates dependency risks. The company's multiple pipeline programs targeting different cancer types and molecular pathways provide some diversification, but each program faces independent clinical and regulatory risks. The radiopharmaceutical space is experiencing intense innovation, with numerous academic institutions and biotech companies developing competing approaches. The company's competitive advantage will ultimately depend on the clinical efficacy of its specific targeting mechanisms and its ability to navigate the complex regulatory and manufacturing challenges inherent in this field.
Risks & safety
Radiopharm presents significant financial risks typical of early-stage biotech companies with minimal revenue and substantial cash burn. • Cash Position: The company held approximately $12.4 million in cash as of June 2024, with annual cash burn of roughly $15-16 million based on free cash flow data, suggesting less than one year of runway without additional financing. • Debt Level: The company maintains a debt-to-equity ratio of 0.0, indicating no significant debt burden, which reduces financial risk but also suggests limited access to debt financing. • Solvency Risk: High immediate solvency risk given the cash burn rate exceeding cash reserves, requiring near-term equity financing or partnership funding. • Valuation Metrics: With negative EBITDA of $29.4 million and minimal revenue, traditional valuation metrics are not meaningful. The recent IPO provides some market validation, but the $6.3 million market cap appears extremely low relative to the company's asset base of $48 million. • Current Ratio: 1.30 indicates adequate short-term liquidity coverage, though this will deteriorate rapidly without additional funding. • Other Considerations: The recent IPO timing suggests management confidence in near-term value catalysts, but also indicates the urgent need for capital to fund operations.
Recent development
As a company incorporated in 2021 and recently public, Radiopharm's development history is relatively brief but focused on establishing a comprehensive radiopharmaceutical pipeline. The company has systematically built its portfolio around key cancer targets, developing both diagnostic and therapeutic applications for each molecular pathway. The strategic partnership with Lantheus Holdings represents a significant validation of Radiopharm's approach and provides access to established nuclear medicine infrastructure and expertise. This relationship appears designed to accelerate clinical development while reducing the capital requirements for specialized manufacturing capabilities. The company has focused on diversifying its pipeline across multiple cancer types and targeting mechanisms, reducing dependence on any single program's success. The development of both diagnostic and therapeutic applications for similar targets (such as RAD 301 and RAD 302 for avß6 integrin) demonstrates a sophisticated understanding of the theranostic approach and potential for creating complementary revenue streams. Recent activities have likely centered on advancing lead programs toward clinical trials and establishing the regulatory and manufacturing partnerships necessary for radiopharmaceutical development. The timing of the IPO suggests the company is preparing to enter more capital-intensive clinical development phases.
RADX company profile · for informational purposes only — not investment advice.
Track RADX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free